Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

Corey Langer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-09-2019 | Non-small-cell lung cancer | Video | Article

    Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

    WATCH  |   Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

  2. 21-01-2020 | Non-small-cell lung cancer | News | Article

    Age no bar for treatment selection in older NSCLC patients

    Editorialists Charu Aggarwal and Corey Langer, both from the University of Pennsylvania in Philadelphia, USA, note that “[t]hese results appear favorable and are approximately comparable to our expectations with immunotherapy in younger patients.”

    Author:
    Shreeya Nanda
    Published in:
    Cancer 2020; doi:10.1002/cncr.32624  Cancer 2020; doi:10.1002/cncr.32573 Cancer 2020; doi:10.1002/cncr.32625
  3. 09-09-2019 | Non-small-cell lung cancer | News | Article

    TMB does not predict NSCLC pembrolizumab–chemotherapy response

    WATCH | Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis (7:35).

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

  4. Simplifying the sequencing of treatment in NSCLC patients with no actionable mutations

    IASLC 20th World Conference on Lung Cancer: Independent satellite symposium Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn This independent symposium, led by an expert international faculty, discussed treatment choices for non-small-cell lung cancer (NSCLC) without targetable mutations, surveying current standards in care against the latest clinical trial data.

  5. 18-10-2016 | Non-small-cell lung cancer | News | Article
    Editor's pick

    Pembrolizumab addition supported in KEYNOTE-021 study

    By comparison, just 29% of the 63 patients who received the chemotherapy alone achieved an objective response, giving a significant estimated treatment difference of 26%, reported lead investigator Corey Langer, from the University of Pennsylvania in Philadelphia, USA.

    Published in:
    Lancet Oncol 2016; Advance online publication; ESMO 2016; Copenhagen, Denmark
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.